Is There a Draft In Here? 21st Century Cures Legislation Stumbles At The Starting Line
This article was originally published in RPM Report
Executive Summary
The House Energy & Commerce Committee released its eagerly awaited first draft of potential legislation to improve the climate for innovation in the US. Or did it? The unexpectedly partisan reaction is a sign of how far the process still has to go – but the overall pro-innovation focus is likely to carry through.
You may also be interested in...
When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street
Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.